Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Watkins

Gastroenterology Chapel Hill, NC Medical Doctor

NPI 1386705366 CMS profile 573301

101 Manning Dr, Chapel Hill, NC 27599

Open in the dashboard

General payments

$876,203

262 records reported · program years 2019–2025

Research payments

$1,250

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$194,699 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Paul Watkins of Chapel Hill, NC is reported in the CMS Open Payments database as having received $876,203 across 262 general payments and $1,250 in research payments paid to them. Separately, studies naming them as principal investigator received $194,699 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $179,702 42
2025 Research $1,250 1
2024 General $92,879 26
2023 General $126,801 38
2022 General $95,952 33
2021 General $99,179 28
2020 General $123,193 29
2019 General $158,498 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Watkins
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Paul Watkins were reported at $179,702. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Paul Watkins Gastroenterology median Middle half National median
2019 $158,498 $417 $126–$1,100 $163
2020 $123,193 $224 $74–$624 $114
2021 $99,179 $352 $106–$1,054 $132
2022 $95,952 $448 $129–$1,270 $149
2023 $126,801 $533 $150–$1,390 $160
2024 $92,879 $605 $160–$1,606 $164
2025 $179,702 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intercept Pharmaceuticals, Inc. $100,947 8 payments
  2. Pfizer Inc. $83,222 27 payments
  3. Mirum Pharmaceuticals, Inc. $54,925 3 payments
  4. Janssen Research & Development, LLC $50,675 16 payments
  5. Actelion Pharmaceuticals, Ltd $48,850 5 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $47,119 8 payments
  7. Merck Sharp & Dohme Corporation $43,473 5 payments
  8. Sarepta Therapeutics, Inc. $27,645 15 payments
  9. AbbVie, Inc. $25,794 15 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $24,848 11 payments
  11. Other $368,706 149 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $859,120 214 payments
  2. Travel and Lodging $8,377 29 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,950 6 payments
  4. Food and Beverage $1,756 13 payments
Products named General payments · program years 2019–2025
  1. Livmarli $54,925 3 payments
  2. Epidiolex $40,393 16 payments
  3. OPSUMIT $30,125 3 payments
  4. Ella $19,247 7 payments
  5. Veozah $14,788 3 payments
  6. Exondys 51 $10,695 5 payments
  7. Turalio $9,450 1 payment
  8. OCREVUS $7,975 2 payments
  9. OCALIVA $6,500 2 payments
  10. SKYRIZI $4,875 2 payments
  11. Other $17,412 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. AbbVie, Inc. $1,250 1 payment

Records

263 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record